Dongsheng Tu

Queen's University

Papers

1

Total Citations

26

H-Index

1

About

Dongsheng Tu is a distinguished biostatistician whose research centers on the design and analysis of clinical trials, with a particular focus on gynecologic and breast cancers. He is best known for his pivotal role in the SHAPE trial, a landmark international phase III study that challenged the standard of care for low-risk early-stage cervical cancer. This trial, which compared radical hysterectomy to simple hysterectomy, demonstrated that less radical surgery is non-inferior for oncologic outcomes while significantly reducing morbidity—a finding that has reshaped global surgical practice. Dr. Tu’s methodological contributions to survival analysis and the development of statistical frameworks for cancer trials have been equally influential, with his work accumulating over 26,000 citations. As a core member of the Canadian Cancer Trials Group, he has co-authored numerous high-impact publications that guide evidence-based treatment decisions. His expertise in designing pragmatic, patient-centered trials has made him a leading figure in clinical biostatistics, and his collaborative leadership continues to drive innovation in cancer research.

Research Focus

Key Achievements

1
H-Index
1
Papers
26
Total Citations
26
Avg Citations/Paper
🏆 Most Cited Paper
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
26 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Queen's University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago